Researchers have developed a portable, breath-based sensor device that detects acetone to measure human fat metabolism with near laboratory-grade precision. Published in the journal Device and created via a collaboration between ETH Zurich and the ETH spin-off Alivion, this hand-held tool offers non-invasive metabolic tracking for diets, diabetes, and clinical therapies.
Tracking active fat metabolism outside a clinical laboratory setting required invasive blood draws or bulky, expensive mass spectrometers. Metabolic monitoring during athletic training, ketogenic medical diets, or weight loss programs has largely relied on generalized metrics rather than real-time biochemical data. That dynamic is shifting following the validation of a new hand-held sensor technology designed to read acetone levels in exhaled human breath.
How the Breath Sensor Detects Fat Metabolism
When the human body shifts from burning carbohydrates like sugar to metabolizing stored fat, it produces acetone as a metabolic by-product. This volatile organic compound travels through the bloodstream, reaches the lungs, and is exhaled. The newly tested portable device operates similarly to a law enforcement alcohol breathalyzer, utilizing advanced gas sensor technology developed at ETH Zurich for over 10 years.
Previous commercial acetone breath testers often suffered from poor reproducibility and cross-sensitivity. They frequently responded to interfering molecules from recent meals or beverages rather than true metabolic shifts. To overcome this limitation, the research team engineered a specialized chemical filter alongside a real-time smartphone application.
“The device measures the volume of exhaled air and only takes a sample that comes from deep in the lungs after a certain time,” explains lead author Simone Hersberger, noting that standardization is essential because otherwise “every reading would be slightly different.” Each unit is calibrated directly to the user’s individual lung volume during initial setup.
Validation Study and Clinical Performance
To establish clinical validity, researchers tested the device in a validation trial involving 12 adult participants, testing its reliability together with the University Hospital Zurich. Across 312 distinct breath readings under various metabolic scenarios—ranging from light to intensive physical activity and contrasting diets—the hand-held prototype performed exceptionally well.
The study compared the device’s output against simultaneous blood test results and high-precision mass spectrometer measurements, which serve as the analytical gold standard. The data revealed that the hand-held unit’s readings were practically identical to lab measurements, maintaining high reliability over a period of months.
“When it comes to diets, there’s no rule of thumb that works for everybody. Ideally, people should self-monitor to see how their own metabolism responds,” states Andreas Güntner, professor of molecular sensing at ETH Zurich’s mechanical and process engineering department. Güntner and his colleagues emphasize the need for independent, reliable testing methods comparable to blood glucose meters used by diabetes patients.
In Plain English: The Clinical Takeaway
- What it measures: The device detects acetone, a chemical gas your lungs release when your body burns fat instead of sugar.
- An internal filter blocks food odors and interference, capturing air from deep in your lungs.
- Why it matters: It eliminates the need for blood tests or lab visits, allowing patients and athletes to track real-time metabolic changes accurately at home.
Expanding Applications in Medical Therapeutics and Public Health
The successful validation study marks a vital milestone for Alivion AG, an ETH Zurich spin-off that has launched the device under the name Nutrion. Nutrion is presently deployed in international research studies and medical facilities. As regulatory bodies and healthcare networks evaluate remote monitoring tools, researchers are looking toward broader clinical translation.
In partnership with the University Children’s Hospital Zurich, investigators are currently assessing whether the breathalyzer can assist children with epilepsy who rely on strict ketogenic diets. Other prospective medical applications include tracking and optimizing metabolic therapies such as GLP-1 therapies with weight loss jabs, alongside broader utilization in amateur sports and personalized medicine.
Funding for the underlying research and development was provided by Innosuisse, the Vontobel Foundation, and the Accentus Foundation. Alivion is actively seeking strategic industry partners and investors to scale up further and open up further fields of application.
| Monitoring Method | Invasiveness | Accuracy / Precision | Primary Use Case |
|---|---|---|---|
| Mass Spectrometer | Non-invasive (Breath) | Gold Standard (Laboratory) | Clinical Research |
| Nutrion Breath Device | Non-invasive (Breath) | High (Validated against Mass Spec) | At-home Tracking, Clinical Studies, Diet Monitoring |
| Blood Biomarker Tests | Invasive (Venous / Finger-prick) | High | Clinical Diagnostics, Diabetes Management |
| Legacy Acetone Breathalyzers | Non-invasive (Breath) | Low (Prone to dietary interference) | General Wellness (Limited reproducibility) |
Contraindications & When to Consult a Doctor
As Alivion AG and researchers at ETH Zurich continue longitudinal studies to evaluate personalized therapy integration, patients and clinicians should view the Nutrion device as an emerging investigational aid.
References:
- Hersberger, S., et al. Device.
- Güntner, A., et al. (2017). ETH Zurich Department of Mechanical and Process Engineering.
- University Hospital Zurich. Clinical validation trials for non-invasive metabolic tracking devices.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding any health condition or therapeutic lifestyle change.
